| abstract |
Pirfenidone for use in the treatment of a patient with idiopathic pulmonary fibrosis (IPF), wherein the patient has level 2 abnormalities in one or more biomarkers of liver function after pirfenidone administration, and has an abnormal level of alanine transaminase (ALT) and / or aspartate transaminase (AST) which is more than 2.5- to 5.0-fold increased compared to the above normal value after administration of pirfenidone, where (a) said patient is administered pirfenidone at doses of at least 1600 mg / day or 1602 mg / day. The application contains 15 more claims . |